Pfizer Global Medical Grants (RFP) Improving Cytogenetic Testing & Treatment Guidance in Adult AML
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Thursday 19th, May 2022
External Deadline: Wednesday 25th, May 2022
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP. For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
Geographic Scope: Canada
Clinical Area: Oncology – Hematology – AML
Link to full RFP: Improving Cytogenetic Testing & Treatment Guidance in Adult AML
Application Due Date: May 25, 2022
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- – Optimizing current cytogenetic testing practices for AML (e.g., pre-analytical sample triaging and processing, increased efficiency and output, reduced turnaround times), and/or,
- – Improving AML patient-related outcomes, which includes earlier access to test results and accurate risk classification and prognostication, leading to improved speed/access to targeted therapies, etc., and/or,
- – Implementing novel or innovative testing methodologies for chromosome and/or genomic analysis for AML classification, aimed at addressing challenges experienced with current testing methodologies.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Jacqueline Waldrop, Grant Officer (Jacqueline.Waldrop@Pfizer.com).